Skip to main content
Français
Search form
Search
Follow the Fraser Institute:
Contact us
About us
Our experts
Donate
Home
Research
Aboriginal Policy
Aging, Retirement, and Pensions
Competitiveness
COVID-19
Economic Freedom
Education Policy
Energy
Environment
ESG - Environmental, Social and Governance
Federal Reform Series
Gov't Spending & Taxes
Health Care
Labour Policy
Monetary Policy and Banking
Municipal Policy
Natural Resources
Poverty and Inequality
Provincial Prosperity
Realities of Socialism
School Report Cards
Essential Scholars
Other Research Topics
More from the Fraser Institute
Education Programs
Western Canada BC, AB, SK, MB, NT, YT, NU
For Students
For Teachers
For Journalists
Central Canada ON, QC, NB, NS, PE, NL
Peter Munk Centre for Free Enterprise Education
For Students
For Teachers
For Journalists
Economic Freedom
School Rankings
Blog
Events
Founders' Award
Other Events
Podcast
Women, Economic Progress, and Markets
Fraser Forum
Donate
Who was Barbara Mitchell?
pharmaceutical Research Archive
An Evaluation of the Proposed PMPRB Amendments
By
Kristina M.L. Acri, née Lybecker
| August 16, 2022
Timely Access to New Pharmaceuticals in Canada, the United States, and the European Union
By
Bacchus Barua, Will Westcott, Van Nghiem Vo
| May 13, 2021
Federal Delays in Approving New Medicines 2013
By
Bacchus Barua, Nadeem Esmail
| April 25, 2013
Average Personal Affordability of Prescription Drug Spending in Canada and the United States 2011
By
Brett J. Skinner, Mark Rovere
| July 21, 2011
Average Personal Affordability of Prescription Drug Spending in Canada and the United States, 2010 edition
By
Brett J. Skinner
| June 10, 2010
